Lefid (Leflunomide)

Leflunomide works by inhibiting the mitochondrial enzyme dihydroorotate dehydrogenase, a key step in de novo pyrimidine synthesis. This limits the proliferation of activated T and B lymphocytes, thereby dampening the immune response and reducing the inflammatory processes that drive rheumatoid and psoriatic arthritis.

The dosage of Lefid is individualized by the prescribing healthcare professional based on the patient’s clinical condition, response, and tolerability. The prescriber determines the appropriate starting dose, any loading regimen, and subsequent maintenance dose, following current clinical guidelines and safety monitoring.

Lefid is classified as pregnancy category X because it is teratogenic and can cause fetal harm. It is contraindicated in pregnant women and should be discontinued well before conception. Breastfeeding is also not recommended, as leflunomide can be excreted in milk and may affect the infant.

To order Lefid, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements), and assist with import documentation.

The primary alternative to leflunomide is methotrexate, another conventional DMARD. While both reduce disease activity, leflunomide has a different mechanism—targeting pyrimidine synthesis—whereas methotrexate inhibits folate metabolism. Lefid may be chosen when methotrexate is ineffective or not tolerated, but both require liver monitoring and have distinct safety profiles.

Lefid tablets should be stored below 25 °C in their original container, protected from moisture and light. Keep the product out of reach of children and avoid exposure to extreme temperatures. No special refrigeration is required for this oral formulation.

Lefid is administered orally as a tablet, usually taken with a full glass of water. It can be taken with or without food, but consistency with regard to meals helps maintain steady absorption. Patients should follow the prescriber’s instructions regarding timing and any required loading dose.

Serious risks associated with Lefid include hepatotoxicity (significant liver enzyme elevation or liver injury), severe infections, hypertension, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored regularly for liver function, blood pressure, and signs of infection, and any concerning symptoms should be reported promptly.

Lefid should not be used by pregnant women, individuals with severe liver disease, uncontrolled hypertension, or active serious infections. It is also contraindicated in patients with known hypersensitivity to leflunomide or any of its excipients. Clinicians must assess each patient’s medical history before initiating therapy.